antibodi
found
wide
applic
treatment
cancer
well
autoimmun
infecti
diseas
sever
dozen
new
antibodi
current
undergo
differ
stage
clinic
trial
soon
ad
list
immunotherapeut
drug
antibodi
gener
use
hybridoma
technolog
phage
display
recent
year
new
method
obtain
human
monoclon
antibodi
activ
develop
method
reli
sequenc
immunoglobulin
gene
b
lymphocyt
well
creation
antibodysecret
stabl
bcell
line
term
nextgener
antibodydiscoveri
platform
alreadi
establish
literatur
refer
approach
review
focus
describ
result
obtain
method
import
recent
advanc
biomed
scienc
associ
develop
clinic
applic
biolog
agent
base
monoclon
antibodi
mab
antibodi
use
immunotherapi
specif
activ
inhibit
certain
cell
function
perform
target
deliveri
chemotherapeut
agent
tumor
cell
neutral
cytokin
deactiv
virus
context
develop
refin
variou
method
human
mab
isol
becom
issu
central
import
first
time
mab
obtain
milstein
use
hybridoma
techniqu
initi
method
could
use
obtain
mous
antibodi
develop
transgen
mous
strain
carri
human
immunoglobulin
gene
becam
possibl
obtain
pure
human
antibodi
despit
rather
old
invent
hybridoma
techniqu
remain
princip
method
mab
product
howev
method
certain
import
shortcom
signific
low
probabl
hybrid
partner
cell
result
effici
obtain
hybridoma
weakli
immunogen
protein
poor
addit
use
transgen
mice
carri
ig
gene
subject
strict
regul
rather
expens
altern
approach
mab
isol
repres
variou
combinatori
techniqu
includ
phage
dna
rna
yeast
display
use
sinc
base
analysi
vast
ig
gene
librari
popular
techniqu
phage
display
alreadi
success
employ
obtain
sever
mab
use
clinic
immunotherapi
particular
adalimumab
inhibit
bind
tumor
necrosi
factor
receptor
howev
compar
hybridoma
technolog
approach
moder
success
princip
shortcom
combinatori
method
result
antibodi
undergo
select
vivo
furthermor
method
frequent
gener
antibodi
nonphysiolog
pair
ig
chain
ie
pair
never
occur
natur
immun
respons
point
view
agent
obtain
use
combinatori
techniqu
consid
antibodi
mimet
like
induc
product
neutral
antibodi
patient
longterm
administr
thu
tradit
approach
base
hybridoma
method
combinatori
techniqu
consider
shortcom
need
new
better
method
obtain
human
mab
review
focus
describ
new
approach
mab
discoveri
base
direct
sequenc
bcell
ig
gene
well
creation
immort
bcell
clone
term
alreadi
coin
techniqu
nextgener
antibodi
discoveri
platform
advent
nextgener
sequenc
ng
techniqu
progress
bioinformat
data
analysi
creat
unpreced
possibl
genom
research
ng
techniqu
enabl
simultan
read
sever
million
variant
singl
gene
especi
import
highli
variabl
ig
gene
repertoir
domain
third
complementaritydetermin
region
antibodi
heavi
chain
alon
may
includ
clonotyp
obvious
repertoir
vh
vl
clonotyp
even
divers
sever
case
ng
applic
mab
product
alreadi
report
bone
marrow
mice
immun
ovalbumin
pool
plasma
cell
isol
analyz
ng
result
vl
vh
repertoir
includ
sever
hundr
thousand
variant
note
repertoir
repres
four
sequenc
led
hypothesi
frequent
occur
sequenc
correspond
antigenspecif
ig
combin
repres
heavi
light
chain
sequenc
express
clone
secret
antigenspecif
antibodi
identifi
screen
ig
gene
character
high
mutat
frequenc
therefor
reliabl
identif
specif
sequenc
requir
whole
variabl
region
read
complet
purpos
read
length
increas
least
bp
fact
threshold
capac
level
modern
ng
analyz
howev
advanc
develop
new
equip
inspir
certain
hope
simultan
progress
softwar
develop
also
contribut
solv
complex
problem
qualiti
read
significantli
improv
employ
uniqu
molecular
identif
tag
bar
code
serv
distinguish
pcr
artifact
rare
mutat
variabl
ig
gene
region
wu
et
al
use
nsg
sequenc
cdna
librari
obtain
antigenspecif
b
cell
isol
blood
hivinfect
donor
first
nucleotid
sequenc
encod
known
broadli
neutral
antibodi
use
deduc
potenti
precursor
gene
cdna
librari
sever
thousand
sequenc
origin
common
embryon
line
precursor
identifi
group
approxim
variant
highest
resembl
select
among
randomli
chosen
express
mab
mab
exhibit
broadrang
neutral
activ
result
indic
ng
applic
discov
novel
mab
princip
shortcom
ngsbase
approach
loss
inform
physiolog
pair
heavi
light
ig
chain
overcom
limit
propos
amplifi
clone
express
antibodi
individu
b
cell
potenti
sourc
ig
gene
plasma
cell
plasmablast
memori
b
cell
tabl
plasma
cell
consid
appropri
object
ig
gene
sequenc
sinc
extens
synthes
antibodi
thu
contain
larg
amount
correspond
mrna
circumst
facilit
procedur
cdna
amplif
howev
plasma
cell
carri
surfac
bcell
receptor
reason
isol
antigenspecif
select
fact
plasma
cell
locat
bone
marrow
also
repres
signific
limit
experi
studi
clargo
et
al
plasma
cell
isol
bone
marrow
rabbit
immun
human
tumor
necrosi
factor
receptor
purpos
bone
marrow
cell
place
gel
growth
medium
contain
antigenload
particl
well
fluoresceinlabel
secondari
antibodi
constant
fragment
rabbit
ig
fluoresc
microscopi
prepar
reveal
antigenproduc
b
cell
surround
fluoresc
halo
form
result
anti
bodi
bind
particl
direct
vicin
produc
plasma
cell
result
nearli
million
bone
marrow
cell
antigenspecif
plasma
cell
isol
recombin
antibodi
endogen
vhvl
pair
obtain
six
antibodi
exhibit
high
level
block
activ
prevent
bind
tumor
necrosi
factor
receptor
studi
corti
et
al
goal
obtain
broadli
neutral
antibodi
influenza
viru
purpos
individu
plasma
cell
isol
blood
vaccin
donor
stimul
allow
plasma
cell
surviv
sever
day
made
possibl
screen
secret
antibodi
broad
panel
viru
subtyp
sequenc
ig
gene
select
cell
author
abl
obtain
broadli
neutral
antibodi
influenza
viru
contrast
plasma
cell
memori
b
cell
express
bcell
receptor
surfac
sort
isol
use
correspond
antigen
howev
start
day
final
immun
blood
level
memori
b
cell
begin
decreas
make
difficult
detect
isol
time
pass
immun
infect
increas
abund
memori
b
cell
transform
epsteinbarr
viru
subsequ
cultiv
particularli
impress
exampl
use
approach
studi
yu
et
al
obtain
human
mab
influenza
viru
strain
associ
spanish
flu
pandem
memori
b
cell
isol
donor
influenza
cell
immort
cultiv
ig
gene
sequenc
express
estim
year
infect
memori
b
cell
present
donor
frequenc
cell
per
b
cell
nevertheless
despit
low
occurr
author
abl
obtain
antigenspecif
antibodi
difficulti
aris
bcell
immort
induc
epsteinbarr
viru
partial
overcom
mean
preliminari
lymphocyt
activ
use
cpgcontain
oligonucleotid
approach
mab
obtain
use
memori
b
cell
blood
patient
recov
sever
acut
respiratori
syndrom
sar
mab
protect
effect
murin
model
infect
caus
sarscov
coronaviru
anoth
exampl
mab
product
use
memori
b
cell
describ
scheid
et
al
memori
b
cell
isol
blood
six
hivinfect
patient
possess
broadli
neutral
antibodi
viru
antigenspecif
memori
b
cell
select
use
bind
viral
protein
carri
fluoresc
label
correspond
ig
gene
sequenc
express
found
immun
respons
mediat
least
independ
clone
target
differ
region
thu
although
popul
memori
b
cell
small
nevertheless
use
obtain
mab
correspond
pathogen
even
long
time
infect
earliest
antibodyproduc
cell
plasmablast
precursor
memori
b
cell
plasma
cell
normal
plasmablast
constitut
small
portion
circul
b
cell
number
increas
dramat
infect
immun
plasmablast
concentr
blood
peak
day
immun
amount
approxim
peripher
b
cell
acut
infect
share
plasmablast
total
number
circul
b
cell
may
reach
smith
et
al
propos
method
enabl
obtain
mab
influenza
viru
anthrax
toxin
pneumococc
antigen
use
plasmablast
fig
accord
method
lymphocyt
isol
donor
blood
day
vaccin
effici
immun
abund
antigenspecif
b
cell
assess
use
enzymelink
immunospot
elispot
techniqu
flow
cytometri
use
sort
plasmablast
phenotyp
one
cell
per
plate
well
mrna
isol
cell
cdna
synthes
rtpcr
amplifi
nest
pcr
follow
algorithm
author
abl
obtain
amount
dna
suffici
subsequ
sequenc
ig
gene
rtpcr
perform
nine
primer
cover
whole
famili
v
fragment
gene
result
two
pcr
product
contain
sequenc
encod
hand
lchain
clone
express
vector
plasmid
use
transfect
cell
express
produc
mab
ml
donor
blood
author
abl
obtain
differ
mab
particular
antibodi
influenza
viru
shown
nearli
b
cell
whole
pool
reactiv
plasmablast
origin
singl
embryon
precursor
current
appropri
method
cell
sort
subsequ
clone
flow
cytometri
import
advantag
includ
high
puriti
result
cell
popul
well
possibl
sort
individu
cell
crucial
clone
purpos
moreov
flow
cytometri
allow
cell
sort
use
combin
detect
paramet
combin
sever
select
paramet
possibl
improv
specif
isol
consider
plasmablast
commonli
isol
base
igg
iga
igm
low
hi
hi
phenotyp
task
simultan
amplifi
sequenc
two
gene
vh
vl
associ
certain
difficulti
facilit
procedur
propos
fuse
gene
earli
experi
subsequ
treat
singl
fusion
gene
order
conveni
express
variabl
ig
sequenc
liao
et
al
develop
special
cassett
contain
necessari
element
gene
transcript
regul
translat
includ
cytomegaloviru
promot
iglead
peptid
constant
fragment
light
heavi
ig
chain
appropri
polya
sequenc
ethic
reason
possibl
immun
human
certain
antigen
strongli
limit
case
immunodefici
scidbeig
mice
use
tempor
host
human
b
cell
human
b
cell
inocul
spleen
subleth
irradi
mice
anim
immun
irradi
serv
achiev
complet
deplet
lymphat
organ
order
enabl
subsequ
lymphopen
prolifer
inocul
lymphocyt
within
free
nich
spleen
day
lymphocyt
transplant
portion
human
plasmablast
higher
use
method
author
obtain
broadli
neutral
antibodi
influenza
viru
singlecel
ig
gene
rtpcr
mention
highthroughput
sequenc
ig
gene
deriv
pool
b
cell
take
account
physiolog
pair
vh
vl
chain
prevent
function
character
endogen
antibodi
furthermor
fairli
difficult
determin
number
sequenc
obtain
ng
relat
number
cell
express
correspond
gene
sequenc
secret
antibodi
comparison
advantag
shortcom
ng
singlecel
ig
gene
sequenc
tabl
suggest
promis
combin
techniqu
experi
studi
tan
et
al
demonstr
possibl
combin
two
approach
b
cell
volunt
donor
vaccin
influenza
viru
sort
plate
well
one
cell
per
well
revers
transcript
cdna
label
bar
code
sequenc
specif
well
follow
pcr
specimen
combin
analyz
use
ng
vh
vl
sequenc
carri
bar
code
correspond
physiolog
correct
pair
light
heavi
ig
chain
mab
influenza
viru
antigen
obtain
base
express
frequent
occur
physiolog
pair
ig
gene
sequenc
sophist
approach
employ
dekoski
et
al
use
socal
pair
vhvl
analysi
blood
b
cell
sort
one
per
well
use
flow
cytometri
well
also
contain
paramagnet
particl
carri
poli
dt
molecul
mrna
bind
follow
cell
lysi
particl
differ
well
combin
emuls
rtpcr
perform
amplifi
cdna
particl
individu
drop
emuls
amplif
perform
overlap
primer
order
obtain
singl
pcr
product
contain
gene
sequenc
heavi
light
ig
chain
fuse
via
short
linker
way
possibl
detect
express
ig
gene
antibodi
broadli
present
immunolog
repertoir
well
correspond
rare
bcell
clone
sequenc
data
obtain
ng
overlap
insuffici
mass
spectrometrybas
proteom
method
addit
employ
determin
amino
acid
sequenc
variabl
ig
domain
obviou
altern
ig
gene
sequenc
purpos
mab
product
might
immort
b
cell
subsequ
clone
cultiv
inde
approach
long
prove
effici
obtain
antigenspecif
cell
clone
howev
seemingli
obviou
experi
bcell
immort
encount
seriou
difficulti
appear
unsurmount
long
time
first
attempt
obtain
constantli
grow
bcell
clone
base
transform
epsteinbarr
viru
howev
cell
exhibit
limit
growth
potenti
low
clone
effici
insuffici
ig
product
level
rapidli
decreas
cultiv
broad
rang
variou
activ
appli
stimul
growth
b
cell
rang
differ
interleukin
tolllik
receptor
ligand
cpgcontain
oligonucleotid
staphylococcu
aureu
divers
approach
test
etern
youth
elixir
could
found
b
cell
far
although
determin
order
maintain
b
cell
divis
essenti
feeder
cell
express
ligand
howev
effici
bcell
stimul
rapidli
underw
termin
differenti
plasma
cell
incap
growth
import
breakthrough
studi
stimul
b
cell
combin
reprogram
due
express
bclxl
transcript
factor
serv
keep
b
cell
plasmablast
state
bclxl
prevent
enter
apoptosi
condit
plasmablast
popul
increas
time
day
cultiv
result
bcell
clone
could
screen
use
produc
requir
antibodi
describ
techniqu
success
appli
obtain
mab
clostridium
tetani
influenza
viru
respiratori
syncyti
viru
parechoviru
divid
plasmablast
express
activationinduc
cytidin
deaminas
enzym
involv
somat
hypermutagenesi
occur
affin
matur
flow
cytometri
antigen
carri
fluoresc
label
use
select
lymphocyt
highest
affin
antigen
total
pool
antigenspecif
b
cell
obtain
antibodi
affin
order
magnitud
higher
initi
popul
approach
provid
new
possibl
obtain
mab
also
improv
thu
recent
research
produc
novel
method
mab
discoveri
number
constantli
grow
everi
reason
believ
nearest
futur
innov
approach
come
play
central
role
develop
novel
drug
immunotherapi
differ
human
diseas
